Emergent BioSolutions (NYSE: EBS) released solid first-quarter results last week. The next few quarters are up in the air due to the transition of the company’s biodefense contract with the government, but management seems unfazed about Emergent’s long-term prospects.
Metric
Q1 2016 Actuals